Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Bioorg Med Chem Lett ; 113: 129940, 2024 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-39233188

RESUMO

Aminopeptidase A (APA) is a membrane-bound zinc metallopeptidase involved in the production of angiotensin III, one effector peptide of the brain renin-angiotensin system, making brain APA a relevant pharmacological target for the development of novel therapeutic treatments against hypertension and heart failure. The structure-based design of new APA inhibitors is described, based on previously developed thiol-containing inhibitors and APA crystal structure. Chemical synthesis, in vitro assessment against APA activity, pharmacological and pharmacokinetic profiling were performed, ultimately leading to a potent and selective APA inhibitor.


Assuntos
Desenho de Fármacos , Glutamil Aminopeptidase , Inibidores de Proteases , Glutamil Aminopeptidase/antagonistas & inibidores , Glutamil Aminopeptidase/metabolismo , Relação Estrutura-Atividade , Inibidores de Proteases/síntese química , Inibidores de Proteases/farmacologia , Inibidores de Proteases/química , Humanos , Animais , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/química , Estrutura Molecular , Ratos , Cristalografia por Raios X , Modelos Moleculares
2.
Clin Sci (Lond) ; 135(6): 775-791, 2021 03 26.
Artigo em Inglês | MEDLINE | ID: mdl-33683322

RESUMO

In the brain, aminopeptidase A (APA), a membrane-bound zinc metalloprotease, generates angiotensin III from angiotensin II. Brain angiotensin III exerts a tonic stimulatory effect on the control of blood pressure (BP) in hypertensive rats and increases vasopressin release. Blocking brain angiotensin III formation by the APA inhibitor prodrug RB150/firibastat normalizes arterial BP in hypertensive deoxycorticosterone acetate (DOCA)-salt rats without inducing angiotensin II accumulation. We therefore hypothesized that another metabolic pathway of brain angiotensin II, such as the conversion of angiotensin II into angiotensin 1-7 (Ang 1-7) by angiotensin-converting enzyme 2 (ACE2) might be activated following brain APA inhibition. We found that the intracerebroventricular (icv) administration of RB150/firibastat in conscious DOCA-salt rats both inhibited brain APA activity and induced an increase in brain ACE2 activity. Then, we showed that the decreases in BP and vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist. Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing Ang 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in vasopressin release induced by RB150/firibastat. RB150/firibastat treatment constitutes an interesting therapeutic approach to improve BP control in hypertensive patients by inducing in the brain renin-angiotensin system, hyperactivity of the beneficial ACE2/Ang 1-7/MasR axis while decreasing that of the deleterious APA/Ang II/Ang III/ATI receptor axis.


Assuntos
Enzima de Conversão de Angiotensina 2/efeitos dos fármacos , Anti-Hipertensivos/farmacologia , Dissulfetos/farmacologia , Glutamil Aminopeptidase/antagonistas & inibidores , Hipertensão/fisiopatologia , Ácidos Sulfônicos/farmacologia , Angiotensina III/metabolismo , Enzima de Conversão de Angiotensina 2/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Acetato de Desoxicorticosterona/administração & dosagem , Modelos Animais de Doenças , Glutamil Aminopeptidase/metabolismo , Hipertensão/induzido quimicamente , Masculino , Camundongos , Ratos Wistar , Cloreto de Sódio na Dieta
3.
FASEB J ; 31(2): 687-700, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27815337

RESUMO

Apelin, a (neuro)vasoactive peptide, plays a prominent role in controlling cardiovascular functions and water balance. Because the in vivo apelin half-life is in the minute range, we aimed to identify metabolically stable apelin-17 (K17F) analogs. We generated P92 by classic chemical substitutions and LIT01-196 by original addition of a fluorocarbon chain to the N terminus of K17F. Both analogs were much more stable in plasma (half-life >24 h for LIT01-196) than K17F (4.6 min). Analogs displayed a subnanomolar affinity for the apelin receptor and behaved as full agonists with regard to cAMP production, ERK phosphorylation, and apelin receptor internalization. Ex vivo, these compounds induced vasorelaxation of rat aortas and glomerular arterioles, respectively, precontracted with norepinephrine and angiotensin II, and increased cardiac contractility. In vivo, after intracerebroventricular administration in water-deprived mice, P92 and LIT01-196 were 6 and 160 times, respectively, more efficient at inhibiting systemic vasopressin release than K17F. Administered intravenously (nmol/kg range) in normotensive rats, these analogs potently increased urine output and induced a profound and sustained decrease in arterial blood pressure. In summary, these new compounds, which favor diuresis and improve cardiac contractility while reducing vascular resistances, represent promising candidates for the treatment of heart failure and water retention/hyponatremic disorders.-Gerbier, R., Alvear-Perez, R., Margathe, J.-F., Flahault, A., Couvineau, P., Gao, J., De Mota, N., Dabire, H., Li, B., Ceraudo, E., Hus-Citharel, A., Esteoulle, L., Bisoo, C., Hibert, M., Berdeaux, A., Iturrioz, X., Bonnet, D., Llorens-Cortes, C. Development of original metabolically stable apelin-17 analogs with diuretic and cardiovascular effects.


Assuntos
Fármacos Cardiovasculares/farmacologia , Diuréticos/farmacologia , Peptídeos/química , Peptídeos/farmacologia , Sequência de Aminoácidos , Animais , Receptores de Apelina , Células CHO , Fármacos Cardiovasculares/química , Cricetinae , Cricetulus , Diuréticos/química , Feminino , Masculino , Camundongos , Ratos , Ratos Sprague-Dawley , Ratos Wistar , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Relação Estrutura-Atividade , Vasoconstrição
5.
Can J Cardiol ; 38(6): 815-827, 2022 06.
Artigo em Inglês | MEDLINE | ID: mdl-35091008

RESUMO

BACKGROUND: Blockade of brain renin-angiotensin system (RAS) overactivity by firibastat, the first centrally acting aminopeptidase A (APA) inhibitor prodrug, has already demonstrated its effectiveness in improving cardiac function after myocardial infarction (MI). We developed QGC606, a more potent and more selective APA inhibitor prodrug and studied its effects after long-term oral administration in mice post-MI. METHODS: Two days after MI induced by the left anterior descending artery ligation, adult male mice were randomized into 4 groups to receive oral treatment during 4 weeks with vehicle; QGC606; firibastat; or the angiotensin-I converting enzyme inhibitor ramipril, used as positive control. RESULTS: Four weeks post-MI, brain APA was overactivated in vehicle-treated MI mice. QGC606 treatment normalized brain APA hyperactivity to control values measured in sham-operated mice. Four weeks post-MI, QGC606-treated mice had higher left ventricular (LV) ejection fractions, significantly smaller LV end-systolic diameter and volume, significantly lower HF biomarkers mRNA expression (Myh7 and Anf) and plasma N-terminal pro B-type natriuretic peptide (NT-pro-BNP) and noradrenaline levels than saline-treated mice. QGC606 treatment significantly improved the dP/dt max and min, LV end-diastolic pressure without affecting blood pressure (BP), whereas we observed a decrease in BP in ramipril-treated mice. We observed also a reduction of cardiac fibrosis, highlighted by lower connective tissue growth factor mRNA levels and a reduction of both the fibrotic area and MI size in QGC606-treated mice. CONCLUSIONS: Chronic oral QGC606 administration in post-MI mice showed beneficial effects in improving cardiac function and reducing cardiac remodeling and fibrosis but, unlike ramipril, without lowering BP.


Assuntos
Insuficiência Cardíaca , Infarto do Miocárdio , Pró-Fármacos , Animais , Fibrose , Glutamil Aminopeptidase , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/etiologia , Humanos , Masculino , Camundongos , Infarto do Miocárdio/complicações , Infarto do Miocárdio/tratamento farmacológico , Miocárdio/patologia , Pró-Fármacos/uso terapêutico , RNA Mensageiro , Ramipril/farmacologia , Ramipril/uso terapêutico , Remodelação Ventricular
6.
Am J Physiol Endocrinol Metab ; 301(5): E955-66, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21846903

RESUMO

Neuronal networks originating in the hypothalamic arcuate nucleus (Arc) play a fundamental role in controlling energy balance. In the Arc, neuropeptide Y (NPY)-producing neurons stimulate food intake, whereas neurons releasing the proopiomelanocortin (POMC)-derived peptide α-melanocyte-stimulating hormone (α-MSH) strongly decrease food intake. There is growing evidence to suggest that apelin and its receptor may play a role in the central control of food intake, and both are concentrated in the Arc. We investigated the presence of apelin and its receptor in Arc NPY- and POMC-containing neurons and the effects of apelin on α-MSH release in the hypothalamus. We showed, by immunofluorescence and confocal microscopy, that apelin-immunoreactive (IR) neuronal cell bodies were distributed throughout the rostrocaudal extent of the Arc and that apelin was strongly colocalized with POMC, but weakly colocalized with NPY. However, there were numerous NPY-IR nerve fibers close to the apelin-IR neuronal cell bodies. By combining in situ hybridization with immunohistochemistry, we demonstrated the presence of apelin receptor mRNA in Arc POMC neurons. Moreover, using a perifusion technique for hypothalamic explants, we demonstrated that apelin-17 (K17F) increased α-MSH release, suggesting that apelin released somato-dendritically or axonally from POMC neurons may stimulate α-MSH release in an autocrine manner. Consistent with these data, hypothalamic apelin levels were found to be higher in obese db/db mice and fa/fa Zucker rats than in wild-type animals. These findings support the hypothesis that central apelin is involved in regulating body weight and feeding behavior through the direct stimulation of α-MSH release.


Assuntos
Hipotálamo/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/fisiologia , Pró-Opiomelanocortina/fisiologia , alfa-MSH/metabolismo , Adipocinas , Animais , Apelina , Hipotálamo/efeitos dos fármacos , Hipotálamo/patologia , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Obesos , Modelos Biológicos , Obesidade/metabolismo , Obesidade/patologia , Pró-Opiomelanocortina/metabolismo , Pró-Opiomelanocortina/farmacologia , Ratos , Ratos Sprague-Dawley , Ratos Wistar , Ratos Zucker , Transdução de Sinais/efeitos dos fármacos
7.
FASEB J ; 24(5): 1506-17, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20040517

RESUMO

Apelin plays a prominent role in body fluid and cardiovascular homeostasis. To explore further upstream the role played by this peptide, nonpeptidic agonists and antagonists of the apelin receptor are required. To identify such compounds that do not exist to date, we used an original fluorescence resonance energy transfer-based assay to screen a G-protein-coupled receptor-focused library of fluorescent compounds on the human EGFP-tagged apelin receptor. This led to isolated E339-3D6 that displayed a 90 nM affinity and behaved as a partial agonist with regard to cAMP production and as a full agonist with regard to apelin receptor internalization. Finally, E339-3D6 induced vasorelaxation of rat aorta precontracted with noradrenaline and potently inhibited systemic vasopressin release in water-deprived mice when intracerebroventricularly injected. This compound represents the first nonpeptidic agonist of the apelin receptor, the optimization of which will allow development of a new generation of vasodilator and aquaretic agents.


Assuntos
Dipeptídeos/farmacologia , Fluoresceínas/farmacologia , Receptores Acoplados a Proteínas G/agonistas , Animais , Aorta/efeitos dos fármacos , Receptores de Apelina , Colforsina/farmacologia , AMP Cíclico/metabolismo , Dipeptídeos/química , Dipeptídeos/isolamento & purificação , Avaliação Pré-Clínica de Medicamentos/métodos , Fluoresceínas/química , Fluoresceínas/isolamento & purificação , Transferência Ressonante de Energia de Fluorescência/métodos , Humanos , Masculino , Camundongos , Ratos , Ratos Endogâmicos WKY , Vasodilatação , Vasopressinas/metabolismo
8.
Biol Aujourdhui ; 215(3-4): 119-132, 2021.
Artigo em Francês | MEDLINE | ID: mdl-35275056

RESUMO

Apelin, a vasoactive neuropeptide, its receptor and arginine-vasopressin (AVP, antidiuretic hormone) are co-localized in magnocellular vasopressinergic neurons. In the kidney, the apelin receptor is present in glomerular arterioles and the collecting duct (CD) where the AVP type 2 (V2-R) receptors are located. Apelin exerts an aquaretic action both by its inhibitory effect on the phasic electrical activity of vasopressinergic neurons and the secretion of AVP into the bloodstream and by its direct actions at the kidney level resulting in an increase in the renal microcirculation and the inhibition of the antidiuretic effect of AVP mediated by V2-R in the CD. Plasma apelin and AVP are conversely regulated by osmotic stimuli in both humans and rodents, showing that apelin is involved with AVP in maintaining body fluid homeostasis. Clinically, in patients with inappropriate antidiuresis syndrome (SIAD), the apelin/AVP balance is altered, which contributes to water metabolism defect. Activation of the apelin receptor by the metabolically stable apelin-17 analog, that increases aqueous diuresis and moderately water intake and gradually corrects hyponatremia, may constitute a new approach for the treatment of SIAD.


Title: Rôle physiologique du récepteur de l'apéline : Implication dans le maintien de l'équilibre hydrique et de l'hyponatrémie. Abstract: L'apéline, un neuropeptide vasoactif, son récepteur (Apéline-R) et l'arginine-vasopressine (AVP, hormone antidiurétique) sont co-localisés dans les neurones magnocellulaires vasopressinergiques. Dans le rein, l'Apéline-R est présent dans les artérioles glomérulaires et le canal collecteur (CD) où sont aussi localisés les récepteurs de l'AVP de type 2 (V2-R). L'apéline exerce une action aquarétique par son effet inhibiteur sur l'activité électrique phasique des neurones vasopressinergiques et la sécrétion systémique de l'AVP dans la circulation sanguine, et par son action directe au niveau du rein. Dans cet organe, elle augmente la microcirculation locale et inhibe, au niveau du CD, l'effet antidiurétique de l'AVP médié par les V2-R. L'apéline et l'AVP dans le plasma sont inversement régulées par les stimuli osmotiques aussi bien chez l'Homme que chez le rongeur, montrant que l'apéline participe avec l'AVP au maintien de l'équilibre hydrique. Sur le plan clinique, chez les patients atteints du syndrome d'antidiurèse inappropriée (SIAD), l'équilibre apéline/AVP est altéré, ce qui contribue au défaut du métabolisme de l'eau. L'activation de l'Apéline-R par un analogue métaboliquement stable d'une des isoformes de l'apéline, l'apéline-17, en augmentant la diurèse aqueuse et modérément la prise d'eau, et en corrigeant progressivement l'hyponatrémie, pourrait constituer une nouvelle approche pour le traitement de cette pathologie.


Assuntos
Receptores de Apelina , Líquidos Corporais , Hiponatremia , Receptores de Apelina/metabolismo , Arginina Vasopressina/metabolismo , Líquidos Corporais/metabolismo , Homeostase , Humanos
9.
Biomed Pharmacother ; 140: 111682, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34020248

RESUMO

In the brain, aminopeptidase A (APA) generates angiotensin III, one of the effector peptides of the brain renin-angiotensin system (RAS), exerting tonic stimulatory control over blood pressure (BP) in hypertensive rats. Oral administration of firibastat, an APA inhibitor prodrug, in hypertensive rats, inhibits brain APA activity, blocks brain angiotensin III formation and decreases BP. In this study, we evaluated the efficacy of firibastat in combination with enalapril, an angiotensin I-converting enzyme inhibitor, and hydrochlorothiazide (HCTZ), in conscious hypertensive deoxycorticosterone acetate (DOCA)-salt rats, which display high plasma arginine-vasopressin levels, low circulating renin levels and resistance to treatment by systemic RAS blockers. We determined mean arterial BP, heart rate, plasma arginine-vasopressin levels and renin activity in DOCA-salt rats orally treated with firibastat, enalapril or HCTZ administered alone or in combination. Acute oral firibastat administration (30 mg/kg) induced a significant decrease in BP, whereas enalapril (10 mg/kg) or HCTZ (10 mg/kg) administered alone induced no significant change in BP in conscious DOCA-salt rats. The BP decrease induced by acute and nine-day chronic tritherapy [Firibastat+Enalapril+HCTZ] was significantly greater than that observed after bitherapy [Enalapril+HCTZ]. Interestingly, the chronic administration of a combination of firibastat with [Enalapril+HCTZ] reduced plasma arginine-vasopressin levels by 62% relative to those measured in DOCA-salt rats receiving bitherapy. Our data show that tritherapy with firibastat, enalapril and HCTZ improves BP control and arginine-vasopressin release in an experimental salt-dependent model of hypertension, paving the way for the development of new treatments for patients with currently difficult-to-treat or resistant hypertension.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Acetato de Desoxicorticosterona/farmacologia , Dissulfetos/farmacologia , Enalapril/farmacologia , Hidroclorotiazida/farmacologia , Hipertensão/tratamento farmacológico , Ácidos Sulfônicos/farmacologia , Vasopressinas/metabolismo , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Animais , Modelos Animais de Doenças , Glutamil Aminopeptidase/metabolismo , Hipertensão/metabolismo , Masculino , Ratos , Ratos Endogâmicos WKY , Sistema Renina-Angiotensina/efeitos dos fármacos
10.
Front Endocrinol (Lausanne) ; 12: 735515, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34880830

RESUMO

Apelin, a (neuro)vasoactive peptide, plays a prominent role in controlling body fluid homeostasis and cardiovascular functions. Experimental data performed in rodents have shown that apelin has an aquaretic effect via its central and renal actions. In the brain, apelin inhibits the phasic electrical activity of vasopressinergic neurons and the release of vasopressin from the posterior pituitary into the bloodstream and in the kidney, apelin regulates renal microcirculation and counteracts in the collecting duct, the antidiuretic effect of vasopressin occurring via the vasopressin receptor type 2. In humans and rodents, if plasma osmolality is increased by hypertonic saline infusion/water deprivation or decreased by water loading, plasma vasopressin and apelin are conversely regulated to maintain body fluid homeostasis. In patients with the syndrome of inappropriate antidiuresis, in which vasopressin hypersecretion leads to hyponatremia, the balance between apelin and vasopressin is significantly altered. In order to re-establish the correct balance, a metabolically stable apelin-17 analog, LIT01-196, was developed, to overcome the problem of the very short half-life (in the minute range) of apelin in vivo. In a rat experimental model of vasopressin-induced hyponatremia, subcutaneously (s.c.) administered LIT01-196 blocks the antidiuretic effect of vasopressin and the vasopressin-induced increase in urinary osmolality, and induces a progressive improvement in hyponatremia, suggesting that apelin receptor activation constitutes an original approach for hyponatremia treatment.


Assuntos
Apelina/sangue , Vasopressinas/sangue , Equilíbrio Hidroeletrolítico/fisiologia , Receptores de Apelina/metabolismo , Encéfalo/metabolismo , Humanos , Neurônios/metabolismo
11.
Front Pharmacol ; 12: 715095, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34393794

RESUMO

Apelin is a neuro-vasoactive peptide that plays a major role in the control of cardiovascular functions and water balance, but has an in-vivo half-life in the minute range, limiting its therapeutic use. We previously developed LIT01-196, a systemically active metabolically stable apelin-17 analog, produced by chemical addition of a fluorocarbon chain to the N-terminal part of apelin-17. LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. We aimed to investigate the effects of LIT01-196 following systemic administrations on arterial blood pressure, heart rate, fluid balance and electrolytes in conscious normotensive and hypertensive deoxycorticosterone acetate (DOCA)-salt rats. Acute i.v. LIT01-196 administration, in increasing doses, dose-dependently decreases arterial blood pressure with ED50 values of 9.8 and 3.1 nmol/kg in normotensive and hypertensive rats, respectively. This effect occurs for both via a nitric oxide-dependent mechanism. Moreover, acute s.c. LIT01-196 administration (90 nmol/kg) normalizes arterial blood pressure in conscious hypertensive DOCA-salt rats for more than 7 h. The LIT01-196-induced blood pressure decrease remains unchanged after 4 consecutive daily s.c. administrations of 90 nmol/kg, and does not induce any alteration of plasma sodium and potassium levels and kidney function as shown by the lack of change in plasma creatinine and urea nitrogen levels. Activating the apelin receptor with LIT01-196 may constitute a novel approach for the treatment of hypertension.

12.
Nat Commun ; 12(1): 305, 2021 01 12.
Artigo em Inglês | MEDLINE | ID: mdl-33436646

RESUMO

Apelin and arginine-vasopressin (AVP) are conversely regulated by osmotic stimuli. We therefore hypothesized that activating the apelin receptor (apelin-R) with LIT01-196, a metabolically stable apelin-17 analog, may be beneficial for treating the Syndrome of Inappropriate Antidiuresis, in which AVP hypersecretion leads to hyponatremia. We show that LIT01-196, which behaves as a potent full agonist for the apelin-R, has an in vivo half-life of 156 minutes in the bloodstream after subcutaneous administration in control rats. In collecting ducts, LIT01-196 decreases dDAVP-induced cAMP production and apical cell surface expression of phosphorylated aquaporin 2 via AVP type 2 receptors, leading to an increase in aqueous diuresis. In a rat experimental model of AVP-induced hyponatremia, LIT01-196 subcutaneously administered blocks the antidiuretic effect of AVP and the AVP-induced increase in urinary osmolality and induces a progressive improvement of hyponatremia. Our data suggest that apelin-R activation constitutes an original approach for hyponatremia treatment.


Assuntos
Apelina/análogos & derivados , Apelina/metabolismo , Arginina Vasopressina/efeitos adversos , Diurese , Hiponatremia/patologia , Hiponatremia/fisiopatologia , Sequência de Aminoácidos , Animais , Apelina/administração & dosagem , Apelina/sangue , Receptores de Apelina/metabolismo , Arginina Vasopressina/sangue , Glicemia/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Linhagem Celular , Colforsina/farmacologia , AMP Cíclico/biossíntese , Desamino Arginina Vasopressina/farmacologia , Modelos Animais de Doenças , Diurese/efeitos dos fármacos , Eletrólitos/sangue , Meia-Vida , Hiponatremia/sangue , Hiponatremia/urina , Túbulos Renais Coletores/efeitos dos fármacos , Túbulos Renais Coletores/metabolismo , Túbulos Renais Coletores/fisiopatologia , Masculino , Camundongos , Modelos Biológicos , Contração Miocárdica/efeitos dos fármacos , Peptídeos/química , Peptídeos/farmacologia , Fosforilação/efeitos dos fármacos , Ratos Sprague-Dawley , Tolvaptan/farmacologia
13.
J Hypertens ; 37(8): 1722-1728, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30882604

RESUMO

OBJECTIVES: We conducted a pilot multicenter double-blind randomized placebo-controlled crossover pharmacodynamic study to evaluate the blood pressure (BP) and the hormonal effects of firibastat, a first-in-class aminopeptidase A inhibitor prodrug, in patients with hypertension. METHODS: Thirty-four patients with daytime ambulatory BP of at least 135/85 mmHg and less than 170/105 mmHg, after a 2-week run-in period were randomly assigned to receive either firibastat (250 mg b.i.d. for 1 week uptitrated to 500 mg b.i.d. for 3 weeks) and then placebo for 4 weeks each or vice versa, with a 2-week washout period on placebo. RESULTS: At 4 weeks, daytime ambulatory systolic BP (SBP) decreased by 2.7 mmHg (95% confidence interval -6.5 to +1.1 mmHg) with firibastat versus placebo (P = 0.157). Office SBP decreased by 4.7 mmHg (95% confidence interval -11.1 to +1.8 mmHg) with firibastat versus placebo (P = 0.151). However, more the basal daytime ambulatory SBP was elevated, more the firibastat-induced BP decrease was marked. Firibastat did not influence 24h-ambulatory heart rate. Firibastat had no effect on plasma renin, aldosterone, apelin and copeptin concentrations. No major adverse events occurred. There was one episode of reversible skin allergy with facial edema. CONCLUSION: In patients with hypertension, a 4-week treatment with firibastat, tended to decrease daytime SBP relative to placebo. Firibastat did not modify the activity of the systemic renin-angiotensin system These results have justified designing a larger, powered trial of longer duration to fully assess its safety and effectiveness. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. NCT02322450.


Assuntos
Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Glutamil Aminopeptidase/antagonistas & inibidores , Hipertensão/tratamento farmacológico , Sistema Renina-Angiotensina/efeitos dos fármacos , Ácidos Sulfônicos/farmacologia , Adulto , Idoso , Anti-Hipertensivos/efeitos adversos , Anti-Hipertensivos/uso terapêutico , Monitorização Ambulatorial da Pressão Arterial , Estudos Cross-Over , Dissulfetos , Método Duplo-Cego , Feminino , Humanos , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Ácidos Sulfônicos/efeitos adversos , Ácidos Sulfônicos/uso terapêutico , Adulto Jovem
14.
J Neurochem ; 106(1): 416-28, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18410507

RESUMO

Aminopeptidase A (APA) generated brain angiotensin III, one of the main effector peptides of the brain renin angiotensin system, exerting a tonic stimulatory effect on the control of blood pressure in hypertensive rats. The distribution of APA in human brain has not been yet studied. We first biochemically characterized human brain APA (apparent molecular mass of 165 and 130 kDa) and we showed that the human enzyme exhibited similar enzymatic characteristics to recombinant mouse APA. Both enzymes had similar sensitivity to Ca(2+). Kinetic studies showed that the K(m) (190 mumol/L) of the human enzyme for the synthetic substrate-l-glutamyl-beta-naphthylamide was close from that of the mouse enzyme (256 mumol/L). Moreover, various classes of inhibitors including the specific and selective APA inhibitor, (S)-3-amino-4-mercapto-butyl sulfonic acid, had similar inhibitory potencies toward both enzymes. Using (S)-3-amino-4-mercapto-butyl sulfonic acid, we then specifically measured the activity of APA in 40 microdissected areas of the adult human brain. Significant heterogeneity was found in the activity of APA in the various analyzed regions. The highest activity was measured in the choroids plexus and the pineal gland. High activity was also detected in the dorsomedial medulla oblongata, in the septum, the prefrontal cortex, the olfactory bulb, the nucleus accumbens, and the hypothalamus, especially in the paraventricular and supraoptic nuclei. Immunostaining of human brain sections at the level of the medulla oblongata strengthened these data, showing for the first time a high density of immunoreactive neuronal cell bodies and fibers in the motor hypoglossal nucleus, the dorsal motor nucleus of the vagus, the nucleus of the solitary tract, the Roller nucleus, the ambiguus nucleus, the inferior olivary complex, and in the external cuneate nucleus. APA immunoreactivity was also visualized in vessels and capillaries in the dorsal motor nucleus of the vagus and the inferior olivary complex. The presence of APA in several human brain nuclei sensitive to angiotensins and involved in blood pressure regulation suggests that APA in humans is an integral component of the brain renin angiotensin system and strengthens the idea that APA inhibitors could be clinically tested as an additional therapy for the treatment of certain forms of hypertension.


Assuntos
Angiotensinas/metabolismo , Vias Autônomas/enzimologia , Pressão Sanguínea/fisiologia , Encéfalo/enzimologia , Glutamil Aminopeptidase/metabolismo , Neurônios/enzimologia , Adulto , Idoso , Animais , Vias Autônomas/anatomia & histologia , Encéfalo/anatomia & histologia , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/fisiologia , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/uso terapêutico , Evolução Molecular , Feminino , Glutamil Aminopeptidase/química , Glutamil Aminopeptidase/isolamento & purificação , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/enzimologia , Hipertensão/fisiopatologia , Masculino , Camundongos , Microcirculação/enzimologia , Pessoa de Meia-Idade , Neuroquímica/métodos , Especificidade da Espécie
15.
J Clin Endocrinol Metab ; 101(5): 1917-23, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-26967692

RESUMO

CONTEXT: Apelin and arginine vasopressin are antagonists in the regulation of body fluid and osmotic homeostasis. There are no data about apelin levels in patients with polyuria-polydipsia syndrome (PPS). OBJECTIVE: To investigate plasma apelin levels and plasma apelin to copeptin ratios in patients with PPS and healthy volunteers using copeptin as a surrogate marker for arginine vasopressin. DESIGN, PARTICIPANTS, AND SETTING: We included 41 patients with PPS in this post hoc analysis of a prospective study performed in tertiary care hospitals in Switzerland and Germany and 113 healthy volunteers as a control group. OUTCOME MEASURES: Plasma apelin and copeptin levels were measured in 15 patients with complete central diabetes insipidus (DI), seven patients with complete nephrogenic DI, 19 patients with primary polydipsia (PP), and 113 healthy volunteers. RESULTS: Plasma apelin levels were highest in patients with complete nephrogenic DI (413 pmol/L; interquartile range, 332-504 pmol/L; P = .01) and lower in patients with PP (190 [172-215] pmol/L; P < .001) or complete central DI (209 [174-241] pmol/L; P = .02) as compared to healthy volunteers (254 [225-311] pmol/L). Plasma apelin to copeptin ratio in patients with PP (53 [38-92] pmol/pmol; P > .9) was similar to healthy volunteers (57 [37-102] pmol/pmol). In contrast, the apelin to copeptin ratio was higher in patients with complete central DI (89 [73-135] pmol/pmol; P = .02) and lower in patients with complete nephrogenic DI (7 [6-10] pmol/pmol; P < .001) compared to healthy volunteers. CONCLUSION: In PP, normal plasma apelin to copeptin ratio attests a normal water homeostasis. In contrast, in patients with central or nephrogenic DI, the increased or decreased apelin to copeptin ratio, respectively, reflects a disturbed osmotic and body fluid homeostasis.


Assuntos
Diabetes Insípido/sangue , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Polidipsia/sangue , Poliúria/sangue , Adulto , Apelina , Feminino , Glicopeptídeos/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Síndrome
17.
Clin Pharmacokinet ; 53(4): 385-95, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24337978

RESUMO

BACKGROUND AND OBJECTIVES: Inhibition of brain aminopeptidase A (APA), which converts angiotensin II into angiotensin III, has emerged as a novel antihypertensive treatment, as demonstrated in several experimental animal models. QGC001 (originally named RB150) is a prodrug of the specific and selective APA inhibitor EC33, and as such it is the prototype of a new class of centrally acting antihypertensive agents. Given by the oral route in hypertensive rats, it enters the brain and generates EC33, which blocks the brain renin-angiotensin system activity and normalises blood pressure. The aim of the present study was to evaluate the safety, pharmacokinetics and pharmacodynamic effects of QGC001 in humans. DESIGN AND METHODS: Fifty-six healthy male volunteers were randomly assigned to receive in double-blind and fasted conditions single oral doses of 10, 50, 125, 250, 500, 750, 1,000 and 1,250 mg of QGC001 (n = 6/dose) or placebo (n = 2/dose). We measured plasma and urine concentrations of both QGC001 and EC33 by liquid chromatography-tandem mass spectrometry, plasma renin concentrations (PRC), plasma and free urine aldosterone (PAldo and UAldo), plasma copeptine (PCop), and plasma and urine cortisol (PCort and UCort) concentrations, and supine systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) at various time points. RESULTS: All doses of QGC001 were clinically and biologically well-tolerated. Peak plasma concentrations (Cmax) of QGC001 and EC33 increased linearly with the dose, with a median time to reach Cmax (tmax) of 1.5 h for QGC001 and 3.0 h for EC33. The median plasma elimination half-life of QGC001 was 1.6 h consistently throughout doses. Urinary excretion of QGC001 and EC33 was below 2% of the administered dose. When compared with placebo, QGC001 did not significantly change PRC, PAldo, UAldo, PCop, PCort or UCort. No significant change was observed for supine HR, SBP and DBP in any treatment group. CONCLUSION: Single oral administration of QGC001 up to 1,250 mg in healthy volunteers was well-tolerated. Following oral administration, QGC001 is absorbed via the gastrointestinal tract and converted partially into its active metabolite EC33 in plasma. As in animal experiments, in normotensive subjects QGC001 had no effect on the systemic renin-angiotensin-aldosterone parameters and on PCop concentrations, a marker of vasopressin release. In normotensive subjects, a single dose of QCG001 had no effect on SBP, DBP or HR. These data support further evaluation of multiple oral doses of QGC001 in human volunteers and its clinical efficacy in hypertensive patients.


Assuntos
Anti-Hipertensivos/farmacologia , Anti-Hipertensivos/farmacocinética , Dissulfetos/farmacologia , Glutamil Aminopeptidase/antagonistas & inibidores , Inibidores de Proteases/farmacologia , Inibidores de Proteases/farmacocinética , Ácidos Sulfônicos/farmacologia , Adolescente , Adulto , Anti-Hipertensivos/administração & dosagem , Arginina Vasopressina/metabolismo , Dissulfetos/administração & dosagem , Dissulfetos/farmacocinética , Relação Dose-Resposta a Droga , Método Duplo-Cego , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pró-Fármacos , Inibidores de Proteases/administração & dosagem , Sistema Renina-Angiotensina/efeitos dos fármacos , Ácidos Sulfônicos/administração & dosagem , Ácidos Sulfônicos/farmacocinética , Adulto Jovem
18.
PLoS One ; 9(2): e87421, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24505289

RESUMO

Normal aging is associated with vasopressin neuron adaptation, but little is known about its effects on the release of apelin, an aquaretic peptide colocalized with vasopressin. We found that plasma vasopressin concentrations were higher and plasma apelin concentrations lower in aged rats than in younger adults. The response of AVP/apelin neurons to osmotic challenge was impaired in aged rats. The overactivity of vasopressin neurons was sustained partly by the increased expression of Transient receptor potential vanilloid2 (Trpv2), because central Trpv blocker injection reversed the age-induced increase in plasma vasopressin concentration without modifying plasma apelin concentration. The morphofunctional plasticity of the supraoptic nucleus neuron-astrocyte network normally observed during chronic dehydration in adults appeared to be impaired in aged rats as well. IL-6 overproduction by astrocytes and low-grade microglial neuroinflammation may contribute to the modification of neuronal functioning during aging. Indeed, central treatment with antibodies against IL-6 decreased plasma vasopressin levels and increased plasma apelin concentration toward the values observed in younger adults. Conversely, minocycline treatment (inhibiting microglial metabolism) did not affect plasma vasopressin concentration, but increased plasma apelin concentration toward control values for younger adults. This study is the first to demonstrate dual vasopressin/apelin adaptation mediated by inflammatory molecules and neuronal Trpv2, during aging.


Assuntos
Envelhecimento/sangue , Astrócitos/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Neurônios/metabolismo , Vasopressinas/sangue , Envelhecimento/patologia , Animais , Antibacterianos/farmacologia , Apelina , Astrócitos/patologia , Regulação da Expressão Gênica/efeitos dos fármacos , Interleucina-6/metabolismo , Masculino , Minociclina/farmacologia , Neurônios/patologia , Pressão Osmótica , Ratos , Ratos Wistar , Canais de Cátion TRPV/biossíntese
19.
J Clin Endocrinol Metab ; 98(5): 2084-9, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23515451

RESUMO

CONTEXT: Apelin and vasopressin levels are regulated in opposite directions to maintain body fluid homeostasis. OBJECTIVE: We thus assessed plasma apelin to copeptin ratios, with plasma copeptin concentrations as a reliable index of vasopressin secretion, in pathological states combining high levels of vasopressin secretion with hyponatremia. DESIGN, PARTICIPANTS, AND SETTING: We carried out a cross-sectional study including 113 healthy subjects, 21 hyponatremic patients with the syndrome of inappropriate antidiuretic hormone (SIADH), and 16 normonatremic and 16 hyponatremic patients with chronic heart failure (CHF) in an academic hospital. OUTCOME MEASURES: Individual apelin to copeptin ratios were plotted against natremia and compared with those of 10 healthy subjects of a previous study acutely challenged by water loading or hypertonic saline infusion. We calculated the percentage of SIADH/CHF patients whose apelin to copeptin ratio for a given natremia lies outside the 95% prediction limits of the physiological relationship. RESULTS: In healthy subjects, median (interquartile range) plasma apelin and copeptin concentrations were 254 fmol/mL (225-311) and 4.0 fmol/mL (2.6-6.9), respectively. Sex- and age-adjusted plasma apelin concentrations were 26% higher in SIADH and normonatremic and hyponatremic CHF patients than in healthy subjects. Sex- and age-adjusted plasma copeptin concentration was 75%, 187%, and 207% higher in SIADH and normonatremic and hyponatremic CHF patients, respectively, than in healthy subjects. During an acute osmotic challenge, the plasma apelin to copeptin ratio decreased exponentially with natremia. Apelin to copeptin ratios as a function of natremia were outside the 95% predicted physiological limits for 86% of SIADH patients and 81% of hyponatremic CHF patients. CONCLUSION: Inappropriate apelin concentrations and apelin to copeptin ratios as a function of natremia in SIADH and CHF patients suggest that the increase in plasma apelin secretion cannot compensate for the higher levels of vasopressin release and may contribute to the corresponding water metabolism defect.


Assuntos
Insuficiência Cardíaca/complicações , Hiponatremia/etiologia , Síndrome de Secreção Inadequada de HAD/fisiopatologia , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Neurofisinas/sangue , Precursores de Proteínas/sangue , Regulação para Cima , Vasopressinas/sangue , Adolescente , Adulto , Idoso , Apelina , Biomarcadores/sangue , Estudos Transversais , Feminino , Glicopeptídeos/sangue , Humanos , Síndrome de Secreção Inadequada de HAD/sangue , Síndrome de Secreção Inadequada de HAD/complicações , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Neurofisinas/metabolismo , Neuro-Hipófise/metabolismo , Precursores de Proteínas/metabolismo , Solução Salina Hipertônica , Vasopressinas/metabolismo , Adulto Jovem
20.
J Neurochem ; 90(6): 1290-301, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15341513

RESUMO

Apelin is a novel neuropeptide involved in the regulation of body fluid homeostasis and cardiovascular functions. It acts through a G protein-coupled receptor, the APJ receptor. We studied the structure-activity relationships of apelin at the rat apelin receptor, tagged at its C-terminal end with enhanced green fluorescent protein and stably expressed in CHO cells. We evaluated the potency of N- and C-terminal deleted fragments of K17F to bind with high affinity to the apelin receptor, and to inhibit cAMP production and to induce apelin receptor internalization. We first characterized the internalization and trafficking of the rat apelin receptor. This receptor was internalized via a clathrin-dependent mechanism and our results suggest that receptor trafficking may follow a recycling pathway. We then tried to identify the amino acids of K17F required for apelin activity. The first five N-terminal and the last two C-terminal amino acids of K17F were not essential for apelin binding or the inhibition of cAMP production. However, the full-length sequence of K17F was the most potent inducer of apelin receptor internalization because successive N-terminal amino-acid deletions progressively reduced internalization and the removal of a single amino acid at the C-terminus abolished this process. Finally, the most novel observation of this work is that hypotensive actions of apelin peptides correlate best with the ability of those ligands to internalize. Thus, apelin receptor signaling and endocytosis are functionally dissociated, possibly reflecting the existence of several conformational states of this receptor, stabilized by the binding of different apelin fragments to the apelin receptor.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Proteínas de Transporte/farmacologia , Endocitose/fisiologia , Receptores Acoplados a Proteínas G/fisiologia , Transdução de Sinais/fisiologia , Animais , Apelina , Receptores de Apelina , Ligação Competitiva/fisiologia , Pressão Sanguínea/fisiologia , Células CHO , Proteínas de Transporte/química , Catepsinas/metabolismo , Cricetinae , Cricetulus , AMP Cíclico/metabolismo , Endocitose/efeitos dos fármacos , Imunofluorescência/métodos , Proteínas de Fluorescência Verde , Frequência Cardíaca/efeitos dos fármacos , Peptídeos e Proteínas de Sinalização Intercelular , Proteínas Luminescentes/metabolismo , Masculino , Proteínas de Membrana/metabolismo , Microscopia Confocal/métodos , Fragmentos de Peptídeos/farmacologia , Ensaio Radioligante/métodos , Ratos , Ratos Endogâmicos WKY , Rodaminas/metabolismo , Transdução de Sinais/efeitos dos fármacos , Relação Estrutura-Atividade , Sacarose/farmacologia , Fatores de Tempo , Transfecção , Proteínas de Transporte Vesicular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA